Why Bone Trauma Still Favors Hydrocodone Over Suzetrigine

Vertex Pharmaceuticals asked a selective NaV1.8 inhibitor to do two jobs at once. Suzetrigine, also known as VX-548, had to beat placebo on a 48-hour pain integral after surgery, and it had to prove superiority over hydrocodone bitartrate/acetaminophen. The first test succeeded in both pivotal studies. The second failed in both, and in orthopedic bone pain the opioid combination was statistically better. That split, not the headline placebo win, is the clinical and commercial fact pattern.

The Phase 3 program ran two randomized, double-blind, placebo-controlled trials in moderate-to-severe acute pain, plus a 256-patient single-arm study across mixed surgical and non-surgical settings. Abdominoplasty enrolled 1,118 patients. Bunionectomy enrolled 1,073. The primary endpoint in both randomized trials was the time-weighted sum of pain intensity difference over 48 hours (SPID48) versus placebo. Abdominoplasty delivered a least-squares mean difference of 48.4 (p < 0.0001). Bunionectomy delivered 29.3 (p = 0.0002). Both cleared the statistical bar Vertex needed for a non-opioid filing narrative.

The Opioid Comparison Vertex Could Not Win

The first key secondary endpoint tested a harder hypothesis: suzetrigine superiority on SPID48 against hydrocodone bitartrate/acetaminophen (HB/APAP) 5 mg/325 mg every 6 hours. In abdominoplasty, the least-squares mean difference versus HB/APAP was 6.6 (p = 0.2781), not statistically significant. In bunionectomy, HB/APAP was superior, with a least-squares mean difference of -20.2 (p = 0.0016) favoring the opioid. Soft-tissue surgery came close to parity. Hard-tissue surgery did not.

That gap is the biological argument in miniature. Bunionectomy is periosteal bone injury. It dumps prostaglandins and multi-channel inflammatory signaling onto nociceptors that are not running on NaV1.8 alone. A highly selective peripheral sodium-channel blockade can blunt one afferent path and still leave prostaglandin, TRP, and other voltage-gated currents intact. Abdominoplasty is primarily soft-tissue trauma. There, single-channel peripheral blockade got closer to opioid-level SPID48. The same molecule, the same dose schedule (100 mg then 50 mg every 12 hours), produced two different competitive pictures because the pain generators were not the same.

Clinicians who treat mixed postoperative lists will read that as a use-case map rather than a binary verdict. Suzetrigine can be an opioid-sparing option where soft-tissue nociception dominates. It is a weaker substitute where bone and periosteum drive the score. Vertex did not hide the secondary miss. The placebo primary still supports efficacy. The active-control numbers define the ceiling against a 5/325 hydrocodone tablet.

Tolerability Is the Other Half of the Trade

Safety is where the non-opioid thesis is strongest. Overall adverse events in suzetrigine arms were lower than placebo: 50.0% versus 56.3% after abdominoplasty, and 31.0% versus 35.2% after bunionectomy. Nausea was 19.0% on suzetrigine versus 32.8% on HB/APAP in abdominoplasty. Dizziness was 4.0% versus 5.4%. There were no drug-related serious adverse events. NaV1.8 is localized to peripheral nociceptors in dorsal root ganglia, which is why the program did not produce the central opioid cluster of sedation, respiratory depression, or addiction liability. The medicine is competing on a benefit-risk ratio, not on raw SPID48 against a Schedule II combination.

That ratio still has to clear a pricing wall. Generic hydrocodone/acetaminophen costs pennies per tablet. A branded NaV1.8 inhibitor cannot win a hospital or ambulatory-surgery formulary on analgesia alone if the comparator is Vicodin economics. Launch math leans on the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act, which created a separate Medicare payment pathway for qualifying non-opioid treatments in outpatient surgical settings. Without that carve-out, a drug that missed opioid superiority in bone pain is an expensive alternative to a generic. With it, the safety profile and the placebo-controlled efficacy can be reimbursed as a policy product: fewer opioid tablets leaving the recovery suite.

What the Split Implies for the Franchise

Vertex is not treating acute pain as a one-indication story. Suzetrigine is also in diabetic peripheral neuropathy and lumbosacral radiculopathy, where the biology is damaged peripheral axons rather than a 48-hour surgical insult. Those settings may suit a peripheral NaV1.8 blocker better than bunionectomy did, or they may expose the same multi-channel problem if radicular and diabetic pain are more than sodium current. Next-generation NaV1.7 assets sit behind the same logic: stack or switch channels if one is not enough.

The Phase 3 package is therefore internally consistent and commercially unfinished. Suzetrigine is an effective non-opioid relative to placebo, cleaner than HB/APAP on nausea, and mechanistically incapable of classic opioid central effects. It is not superior to a cheap opioid combination, and in hard-tissue surgery it is inferior on the same endpoint that won the placebo comparison. Anyone modeling the franchise has to hold both results at once: a real analgesic signal, a real active-control miss, and a reimbursement statute that may matter more than the p-value against hydrocodone.